AstraZeneca
New HER2-Positive Breast Cancer Therapy Launched by AstraZeneca in the Middle East
AstraZeneca Iraq has registered a new targeted therapy for advanced HER2-positive breast cancer. Utilizing advanced Antibody-Drug Conjugate (ADC) technology, the treatment aims to improve outcomes for the most diagnosed cancer among Iraqi women, aligning with regional trends in specialized oncology.
Mohamed Mosaed ·